Comparison of short- and long-term humoral immune responses to pneumococcal polysaccharide and glycoconjugate vaccines in an HIV-infected population.
Faustini SE. et al, (2024), J Infect, 89
Evaluation of a Quadrivalent Shigella flexneri Serotype 2a, 3a, 6, and Shigella sonnei O-Specific Polysaccharide and IpaB MAPS Vaccine.
Boerth EM. et al, (2024), Vaccines (Basel), 12
Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries.
Giersing BK. et al, (2023), Lancet Glob Health, 11, e1819 - e1826
Efficient Autotransporter-Mediated Extracellular Secretion of a Heterologous Recombinant Protein by Escherichia coli.
Beriotto I. et al, (2023), Microbiol Spectr, 11
Salmonella Combination Vaccines: Moving Beyond Typhoid.
MacLennan CA. et al, (2023), Open Forum Infect Dis, 10, S58 - S66
Severe anaemia, iron deficiency, and susceptibility to invasive bacterial infections
Abuga KM. et al, (2023), Wellcome Open Research, 8, 48 - 48
Consequences of Shigella infection in young children: a systematic review.
Libby TE. et al, (2023), Int J Infect Dis
Complementary measurement of nontyphoidal Salmonella-specific IgG and IgA antibodies in oral fluid and serum.
Elias SC. et al, (2023), Heliyon, 9
Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines.
Micoli F. et al, (2023), Front Mol Biosci, 10
Immune responses to Neisseria gonorrhoeae and implications for vaccine development.
Belcher T. et al, (2023), Front Immunol, 14
Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data.
Cohen D. et al, (2022), Clin Microbiol Infect
Impact and Control of Sugar Size in Glycoconjugate Vaccines.
Stefanetti G. et al, (2022), Molecules, 27
Frontiers in Shigella Vaccine Development.
MacLennan CA. and Steele AD., (2022), Vaccines (Basel), 10